ADC Therapeutics has announced that the first patient has been dosed in its Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and anti-tumour activity of ADCT-402 in combination with AstraZeneca's Imfinzi in patients with advanced diffuse large B-cell lymphoma, mantle cell lymphoma or follicular lymphoma.Original Article
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.